Pipeline

Ray Therapeutics is pursuing multiple drug development programs for a range of degenerative retinal diseases, focusing on preserving and restoring vision in patients using the ground-breaking science of optogenetics.

Indication

Product Candidate

Discovery

Pre-IND

IND Enabling

Phase 1

Retinitis Pigmentosa

Genotype agnostic

RAY-001

Pre-IND

Other Inherited retinal diseases

Choroideremia 
Stargardt’s disease

RAY-001

Discovery

Geographic Atrophy

RAY-002

Discovery